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Abstract Lithium can interfere with embryonal development in
a variety of organisms. We investigated the effect of lithium on
the proliferation of early embryonal cells. [3H]Thymidine
incorporation of non-committed mouse P19 embryonal carcino-
ma cells was inhibited by lithium treatment. Similar effects were
seen in a variety of other cells. This growth inhibition occurred in
the G2 phase, since cells accumulated with a 4N DNA content,
but the appearance of mitotic cells was blocked. Lithium could
also prevent the activation of cdc2, thereby inhibiting cyclin
B/cdc2 kinase activity. These data indicate that lithium might
disturb embryonal development through interference in embry-
onal cell cycle regulation.
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1. Introduction
Early embryonal stem cells undergo rapid cycles of cell
division, but the cell cycle lengthens as cells become more
committed. This lengthening is due to the introduction of
cell cycle control mechanisms, causing the cells to pause be-
tween the alternating S and M phases, in G1 or G2 [1]. During
G2, initiation of mitosis is prevented by inhibitory phospho-
rylation of the mitotic cyclin B/cdc2 complexes. This inhibi-
tory phosphorylation takes place on the Thr-14 and Tyr-15
residues of cdc2 and is mediated by Wee1 and related kinases
[2^5]. At the end of the G2 phase, the phosphatase Cdc25C
dephosphorylates these inhibitory sites, triggering the activa-
tion of cdc2 [6,7].
Lithium is used as a treatment for bipolar psychiatric dis-
orders [8]. In addition, it has been demonstrated that lithium
can stimulate proliferation of some cells [9] and has terato-
genic e¡ects [10,11], when used at concentrations applied in
human therapy. For example, in Xenopus embryos, lithium
works as a modi¢er of mesoderm induction that can induce
duplication of the dorsal axis [10]. In Dictyostelium, lithium
in£uences cell fate determination by blocking spore cell and
promoting stalk cell development [11].
In this paper, we demonstrate that lithium inhibits the pro-
liferation of mouse embryonal cells, as well as in a variety of
other cell lines. The e¡ect of lithium is exerted in the G2 phase
and is associated with an inhibition of cyclin B-associated
kinase activity, due to retention of phosphorylation on the
Tyr-15 regulatory site of cdc2.
2. Materials and methods
2.1. Cell culture, antibodies and reagents
U2OS (ATCC), A14 [12] and Rat-1 (ATCC) cells were routinely
grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM, Gibco). P19
cells (ATCC) were also cultured in DMEM, on gelatin-coated dishes.
SK-N-MC (ATCC) cells were cultured in a 1:1 mixture of DMEM
and Ham’s F12 (DF12 medium, Gibco). The culture media were
supplemented with 10% fetal calf serum (FCS, Integro), 2 mM
L-glutamine, 100 U/ml penicillin and 100 Wg/ml streptomycin. For
di¡erentiation, P19 cells were grown in aggregates on bacteriological
petri dishes in the presence of retinoic acid (RA) 1036 M for 5 days
(P19AG+RA) [13]. Cells were arrested at the metaphase/anaphase
transition of the M phase by treating the cells with nocodazole
(2.5 Wg/ml; Sigma) for 16 h [14]. To arrest the cells at the G1/S
transition, cells were treated with thymidine (2.5 mM; Sigma) for
24 h. Cells were released from a thymidine block by washing twice
with pre-warmed PBS, followed by washing twice with pre-warmed
culture medium for 15 min at 37‡C.
Protein A/G plus agarose, and the mouse monoclonal antibodies
against cyclin B1 (GNS1) and cdc2 (clone 17) were purchased from
Santa Cruz. Polyclonal phosphospeci¢c cdc2-Tyr-15 antibody was
obtained from New England Biolabs. Histone H1 was obtained
from Boehringer Mannheim. Propidium iodide was purchased from
Sigma.
2.2. [3H]Thymidine incorporation assay and cell cycle analysis
[3H]Thymidine incorporation was performed as described [15].
For DNA pro¢les, the cells were grown with or without LiCl
(10 mM) for 48 h, after which cells were harvested and ¢xed overnight
in 70% ethanol at 4‡C. After washing away the ethanol, the cells were
stained with propidium iodide in a solution containing 10 Wg/ml pro-
pidium iodide and 10 Wg/ml DNase-free RNase. The stained cells were
analyzed on a £uorescence activated cell sorter (FACS) using Lysis II
software £ow cytometry analysis (Becton Dickinson).
To determine the percentage of mitotic cells, cells were harvested,
¢xed in 70% ethanol and cytospins were prepared. DNA was stained
using 4P,6-diamidino-2-phenylindole (DAPI, 20 Wg/ml) [16]. The per-
centage of mitotic ¢gures was scored using £uorescence microscopy
(v 200 cells per time point).
2.3. Western blotting, immunoprecipitation and in vitro kinase reactions
For Western blotting, cells were lysed directly in Laemmli sample
bu¡er without L-mercaptoethanol or bromophenol blue and the sam-
ples were boiled for 5 min. Protein concentrations were determined
using the Lowry protein assay [17]. Subsequently, L-mercaptoethanol
and bromophenol blue were added. Proteins were separated on a
polyacrylamide (PAA) gel and blotted to a nitrocellulose membrane.
Proteins were detected with antibody incubation (mouse monoclonal
anti-cdc2, recognizing human, mouse and Xenopus cdc2, non-cross-
reactive with other cdks; rabbit polyclonal phosphospeci¢c anti-cdc2-
Tyr-15) overnight at 4‡C. This was followed by the secondary anti-
body for 1 h at room temperature. The blots were developed using
enhanced chemiluminescence (ECL).
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 0 0 2 - 9
*Corresponding author. Fax: (31) (30) 2511893.
E-mail: r.h.medema@lab.azu.nl
Abbreviations: DAPI, 4P,6-diamidino-2-phenylindole; ECL, enhanced
chemiluminescence; FACS, £uorescence activated cell sorter; GSK-3,
glycogen synthase kinase 3; IMPase, inositol monophosphatase;
PAA, polyacrylamide; RA, retinoic acid
FEBS 22450 16-8-99
FEBS 22450 FEBS Letters 457 (1999) 23^27
For immunoprecipitation, the cells were washed with ice-cold PBS
and lysed in NETN (400 mM NaCl, 20 mM Tris pH 8.0, 1 mM
EDTA, 0.5% NP-40 supplemented with 10 mM L-glycerophosphate,
10 mM NaF, 1 mM Na2VO3, 1 mM phenylmethylsulfonyl £uoride,
10 Wg/ml aprotinin, 10 Wg/ml leupeptin and 10 Wg/ml trypsin inhibitor)
for 30 min at 4‡C. Lysates were centrifuged at 15 000 rpm at 4‡C.
Cyclin B1 was immunoprecipitated with 0.3 Wg of anti-cyclin B1 anti-
body and protein A/G plus agarose for 4 h to overnight at 4‡C.
Subsequently, immmunoprecipitates were washed three times with
lysis bu¡er. For cdc2 immunoblotting, precipitates were washed
once again with lysis bu¡er, after which sample bu¡er was added.
Then the samples were boiled for 5 min, the proteins were separated
on a 12% PAA gel and cdc2 was detected by Western blotting. In
vitro kinase reactions were performed as described [15].
3. Results
3.1. Lithium inhibits proliferation of P19 cells
To study if lithium can a¡ect the proliferation of early
embryonal cells, we used mouse P19 embryonal carcinoma
cells as a model for embryonal cells [18]. We found that pro-
liferation was dramatically inhibited, as determined by
[3H]thymidine incorporation (Fig. 1A). To determine whether
this e¡ect was restricted to non-committed early embryonal
cells, we analyzed the e¡ect of lithium on proliferation in
di¡erentiated P19 cells. To this end, P19 cells were cultured
in aggregates in the presence of RA for 5 days, inducing
mesodermal and neuronal di¡erentiation [13]. Treating such
di¡erentiated P19 cells for 24 h or 48 h with LiCl resulted in a
decrease of [3H]thymidine incorporation of V30% and
V45%, respectively (Fig. 1A). Although the e¡ect of lithium
is not as dramatic in the di¡erentiated P19 cells compared to
the undi¡erentiated cells, we do not think this is due to a
di¡erence in sensitivity to lithium but rather to the slower
proliferation rate of the di¡erentiated cells.
In addition, we examined the dose dependence of growth
inhibition by lithium. As shown in Fig. 1B, proliferation is
already inhibited at a concentration of 0.5 mM LiCl.
To determine in which phase of the cell cycle lithium exerts
its growth-inhibitory e¡ect, we analyzed cell cycle pro¢les of
asynchronously growing P19 cells, which were treated with
LiCl for 48 h. Treatment with LiCl resulted in an increase
in the number of cells with a 4N DNA content from 26%
in untreated cells to 47% in LiCl-treated cells (Fig. 1C).
Also di¡erentiated P19 cells showed an accumulation of
cells in the G2/M phases upon LiCl treatment (data not
shown).
3.2. Lithium induces growth inhibition in several cell lines
To analyze if the e¡ect of lithium on G2/M progression is
more general, we investigated its e¡ect on the proliferation of
a diverse range of cell lines. The e¡ect of lithium on DNA
synthesis in U2OS cells (human osteosarcoma), SK-N-MC
cells (human neuroepithelioma), Rat-1 cells (rat ¢broblast)
and NIH 3T3-derived A14 cells (mouse ¢broblast) was deter-
mined by [3H]thymidine incorporation in the absence or pres-
ence of LiCl. Treatment of U2OS, SK-N-MC and A14 cells
with LiCl resulted in a decrease of [3H]thymidine incorpora-
tion from V45% in SK-N-MC cells to V60% in U2OS cells
and up to V75% in A14 cells (Fig. 2A). [3H]Thymidine in-
corporation in Rat-1 cells was not in£uenced by LiCl treat-
ment (Fig. 2A).
Also in these cells the growth inhibition occurred in G2/M.
Treating U2OS cells with LiCl for 24 h resulted in an increase
in the 4N population from 20% to 32% (data not shown),
whereas treatment for 48 h resulted in an increase up to
49% (Fig. 2B). Treatment of SK-N-MC cells and A14 cells
with LiCl also resulted in an increase in the amount of cells in
the G2/M phase (data not shown), indicating that lithium has
a similar e¡ect on a diverse range of cell lines.
3.3. Lithium inhibits G2 phase progression, not mitosis
To determine whether lithium-treated cells are blocked in
Fig. 1. Lithium inhibits proliferation of P19 cells by a block in G2/
M. A: Asynchronously growing P19 cells or di¡erentiated P19 cells
(P19AG+RA) were seeded in 24-well dishes at 40 000 cells per well.
After 24 h, the cells were left untreated (white bars) or treated with
LiCl (10 mM) for 24 (gray bars) or 48 h (black bars).
[3H]Thymidine incorporation was determined in triplicate and is
represented as percentage incorporation of untreated cells (actual,
P19: 14U105 cpm/well; P19AG+RA: 0.7U105 cpm/well). Error bars
represent the S.E.M. B: Asynchronously growing P19 cells were
seeded in 24-well dishes at 10 000 cells per well. After 24 h, the cells
were treated with di¡erent concentrations of LiCl for 24 h.
[3H]Thymidine incorporation was determined as described in A. C:
Asynchronously growing P19 cells were left untreated or treated
with LiCl (10 mM). After 48 h, the cells were harvested and cell
cycle pro¢les were obtained by staining with propidium iodide.
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the G2 phase or in M phase, we tested whether lithium could
inhibit cells from entering mitosis. To this end, U2OS cells
were treated with nocodazole, to arrest them at the meta-
phase/anaphase transition of the M phase, in the presence
or absence of LiCl. At several time points, cells were har-
vested and the percentage of mitotic cells was determined by
immuno£uorescence staining with the DNA-interchelating
dye DAPI. In the samples treated with nocodazole, the ¢rst
mitotic cells appeared within 6 h (Fig. 3). The percentage of
mitotic cells increased with time and after 16 h a large per-
centage of the cells (V56%) was in the M phase. In contrast,
cells treated with nocodazole and LiCl clearly showed a delay
in entering mitosis. After 16 h, we could only detect V12%
mitotic cells.
In addition, U2OS cells were synchronized at the G1/S tran-
sition using thymidine. When the cells were released in the
presence of LiCl the appearance of mitotic cells was delayed
compared to the untreated cells (data not shown), again
indicating that the block occurs prior to initiation of mito-
sis.
3.4. Lithium prevents the activation of cdc2
For entering M phase, kinase activity of the mitotic cyclin
B/cdc2 complex is required [3]. We therefore investigated if
lithium could interfere with the activation of the cyclin B/cdc2
kinase. To do so, U2OS cells were synchronized at the G1/S
transition using thymidine. Next, the cells were released in the
presence or absence of LiCl, and nocodazole was added, to
ensure that the synchronized cells eventually block at the
metaphase-anaphase transition of the M phase. At di¡erent
time points after the release, we measured cyclin B-associated
kinase activity (Fig. 4A). Kinase activity in the untreated
samples rose 16 h after the release and increased with time.
In contrast, we observed only a minor increase in cyclin B-
associated activity in cells released from the thymidine block
in the presence of LiCl. This increase occurred at a later time
point and the overall kinase activity remained low.
The reduction in cyclin B/cdc2 kinase activity was not due
to inhibition of cyclin B expression, since cyclin B protein
levels were not in£uenced by lithium treatment (data not
shown).
We next analyzed the phosphorylation state of cdc2 after
treatment with lithium. Cyclin B immunoprecipitations ob-
tained at the same time points after release from the thymi-
dine block were subjected to immunoblotting for cdc2. De-
phosphorylation of the Tyr-15 residue of cdc2 leads to the
activation of cdc2 at the G2/M transition and results in a
mobility shift on PAA gels [19]. In cells blocked at the G1/S
transition using thymidine, only the slower migrating form of
cdc2 could be detected (Fig. 4B). This form represents the
inactive form of cdc2, phosphorylated on Tyr-15 [19], which
we con¢rmed with a phosphospeci¢c cdc2-Tyr-15 antibody
(Fig. 4B). Activated cdc2 was present after a 13 h release in
the absence of LiCl and the amount of Tyr-15-dephospho-
rylated protein increased with time. Releasing the cells in
the presence of LiCl showed that cyclin B/cdc2 complex for-
mation occurred normally, but the Tyr-15 dephosphorylation
was inhibited. After 25 h V80% of the cdc2 is in its activated,
faster migrating form in untreated samples, whereas in the
samples treated with LiCl, only V20% of the cdc2 is active.
As is shown in Fig. 4C, the inhibition of Tyr-15 dephos-
phorylation of cdc2 shows a very similar concentration de-
pendence for LiCl as was observed for the inhibition of
[3H]thymidine incorporation (Fig. 1B).
Fig. 2. Lithium inhibits proliferation of A14, U2OS and SK-N-MC
cells, but not Rat-1 cells. A: U2OS, SK-N-MC, Rat-1 and A14 cells
were seeded in 24-well dishes at 40 000 cells per well. After 24 h,
the cells were left untreated (white bars) or treated with LiCl (10
mM) for 24 (gray bars) or 48 h (black bars). [3H]Thymidine incor-
poration was determined in triplicate and is represented as percent-
age incorporation of untreated cells (actual, 1.2U105 to 4.2U105
cpm/well). Error bars represent the S.E.M. B: U2OS cells were left
untreated or treated with LiCl (10 mM) for 48 h. Then, the cells
were harvested and cells cycle pro¢les were obtained by staining
with propidium iodide.
Fig. 3. Lithium inhibits M phase entry. U2OS cells were treated
with nocodazole in the absence (closed circles) or presence (open
circles) of LiCl (10 mM). At di¡erent time periods, cells were har-
vested. Then, DNA was stained using DAPI. The percentage of mi-
totic cells was determined by scoring for cells with condensed chro-
mosomes, using immuno£uorescence microscopy.
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4. Discussion
In this paper, we show that lithium induces a G2 arrest in a
variety of cell lines and inhibits the appearance of cyclin B/
cdc2 kinase activity. This inhibition is due to retention of
inhibitory phosphorylation of Tyr-15 on cdc2. Dephosphoryl-
ation of cdc2-Tyr-15 is a critical step in the activation of the
cyclin B/cdc2 complex [6,7]. Our results suggest that lithium
might prevent the activation of the mitotic cyclin B/cdc2 com-
plex, through interference with Tyr-15 dephosphorylation.
Two di¡erent pathways have been described by which lith-
ium could a¡ect embryonal development. Lithium has been
shown to inhibit inositol monophosphatase (IMPase) in vitro
[20,21] and lithium can act as an inhibitor of glycogen syn-
thase kinase 3 (GSK-3) and thereby mimic Wingless signaling
[22,23]. Whether one of these pathways is involved in the
e¡ect of lithium we describe here is currently unknown.
DNA damage will also result in an arrest in G2 progression
and this arrest is caused by inhibition of cdc2 dephosphoryl-
ation [24]. Recent studies showed that the inhibition of cdc2
activation after DNA damage is mediated by the inactivation
of Cdc25C [25,26] through phosphorylation-dependent bind-
ing to 14-3-3 [27^29]. Present cancer therapies mostly rely on
the increased sensitivity of tumor cells to a variety of DNA-
damaging agents. Since lithium seems to interfere with the
same pathway as these agents, it will be of signi¢cant interest
to identify the target(s) of lithium and to investigate the rel-
ative sensitivity of normal and tumor cells to lithium treat-
ment. In that respect, it is very interesting that lithium has
been reported to reduce the incidence of cancer [30].
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